Insight into p95HER2 in breast cancer: Molecular mechanisms and targeted therapies

Recent Patents on DNA and Gene Sequences

Volumn 6, Issue 1, 2012, Pages 56-63

  de Mello, Ramon Andrade ^a,b   de Vasconcelos, Alessandro ^c   Ribeiro, Ronaldo A ^d,e   Pousa, Inês ^a   Afonso, Noémia ^a   Pereira, Deolinda ^a   Rodrigues, Helena ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b University of Porto   (Portugal)

^c São Rafael Hospital Monte Tabor Foundation   (Brazil)

^d FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^e Instituto do Cancer do Ceara   (Brazil)

Author keywords

Biomarkers; Breast neoplasms; ErbB 2; Genes; Human HER2 protein; Lapatinib; Monoclonal antibodies; Neratinib; P95HER2; Pertuzumab; Pharmacogenetics; Trastuzumab; Trastuzumab DM1

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; LAPATINIB; MAYTANSINE; METHOTREXATE; NAVELBINE; NERATINIB; P95 EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB MAYTANSINE; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; DIARRHEA; DRUG TOLERABILITY; FATIGUE; GENE OVEREXPRESSION; HUMAN; HYPOKALEMIA; INFECTION; METASTASIS; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOCONJUGATES; PATENTS AS TOPIC; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 84857126212     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221512799303109     Document Type: Article

References (59)

1. Jemal A, Bray F, Center M, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. de Mello R, Figueiredo P, Marques M, et al. Concurrent breast stroma sarcoma and breast carcinoma: a case report. J Med Case Reports 2010; 4: 414.
3. Singletary S, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-36.
4. Swaby R, Cristofanilli M. Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC Med 2011; 9: 43.
5. Arribas J, Baselga J, Pedersen K, Parra-Palau J. p95HER2 and breast cancer. Cancer Res 2010; 71: 1515-9.
6. Schechter A, Stem D, Vaidyananthan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312: 513-6.
7. Agus D, Akita R, Fox W, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-37.
8. Klappler L, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999; 96: 4995-5000.
9. Klapper L, Kirschbaum M, Sela M, Yarden Y. Biochemical and clinical implications of ErbB/HR signaling network of growth factor receptors. Adv Cancer Res 2000; 77: 25-79.
10. Mendoza N, Phillips G, Silva J, Schwall R, Wickramasinghe D. Inhibition of Ligand-mediated HER2 Activation in Androgenindependent Prostate Cancer. Cancer Res 2002; 62: 5485-8.
11. Ahn E, Vogel C. Dual HER2-targeted approaches in HER2- positive breast cancer. Breast Cancer Res Treat 2011; DOI 10.1007/s10549-011-1781-y.
12. de Mello R, Marques D, Medeiros R, Araújo A. Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol 2011; 2: 367-76.
13. Mukohara T. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Sci 2011; 102: 1-8.
14. Hubalek M, Brunner C, Matthä K, Marth C. Resistance to HER2- targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Med Wochenschr. 2010; 160: 506-12.
15. Azim H, Azim HJ. Optimizing the Use of Her-2/neu Targeting Agents in Breast Cancer: A Developing Nation Perspective. J Egypt Natl Canc Inst 2007;19: 225-30.
16. Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007; 99: 628-38.
17. Clinton G. N-Terminally truncated HER-2/Neu protein as a cancer prognostic indicator. US 6541214 B1, 2003.
18. Parra-Palau J, Pedersen K, Peg V, et al. A major role of p95/611- CTF, a carboxy-terminal fragment of HER2, in the downmodulation of the estrogen receptor in HER2-positive breast cancers. Cancer Res 2010; 70: 8537-46.
19. Sperinde J, Jin X, Banerjee J, et al. Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer. Clin Cancer Res. 2010; 15: 4226-35.
20. Sáez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006; 12: 424-31.
21. Spector N, Xia W. Treatment of cancers expressing p95 ErbB2. US 7829297, 2010.
22. Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99: 628-38.
23. Scaltriti M, Chandarlapaty S, Prudkin L, et al. Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clin Cancer Res 2010; 16: 2688-95.
24. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol 2010; 21: vii36-vii40.
25. Hudis C. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
26. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 2011; 11: 263-75.
27. Paton V, Shak S, Hellmann S. Treatment with anti-ErbB2 antibodies US 7892549, 2011.
28. Gianni L, Dafni U, Gelber R, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12: 236-44.
29. Perez EA, Romond EH, Suman VJ, et al. Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-73.
30. Slamon D, Eiermann W, Robert N. BCIRG 006: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→ T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→ TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX: Cancer Res; 2009.
31. Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCCPACS 04 trial. J Clin Oncol 2009; 27: 6129-34.
32. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27: 5685-92.
33. Vici P, Viola G, Botti C, et al. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Clin Ter 2008; 159: 449-52.
34. Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 188-94.
35. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2- positive operable breast cancer. J Clin Oncol 2005; 23: 3676-85.
36. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13: 228-33.
37. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2- positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2- negative cohort. Lancet 2010; 375: 377-84.
38. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the Gepar Quattro study. J Clin Oncol 2010; 28: 2024-31.
39. Nakayama T, Morita S, Takashima T, et al. Phase I Study of S-1 in Combination with Trastuzumab for HER2-positive Metastatic Breast Cancer. Anticancer Res 2011; 31: 3035-9.
40. Morrow PK, Wulf GM, Ensor J, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011; 29: 3126-32.
41. van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 2010; 16: 3094-9.
42. Nahta R, O'Regan RM. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/ mTOR pathway. Clin Breast Cancer 2010; 10: 72-8.
43. Gajria D, Gonzalez J, Feigin K, et al. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2011:DOI 10.1007/s10549-011-1749-y.
44. Bouchalovaa K, Cizkovaa M, Cwiertkab K, et al. Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma levela assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154: 281-8.
45. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
46. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008; 29: 217-33.
47. Johnston S, Pippen Jr J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-46.
48. Guarneri V, Barbieri E, Dieci M, Piacentini FPC. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev 2010; 36: S62-6.
49. Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009; 69: 9330-6.
50. Fang L, Barekati Z, Zhang B, Liu Z, Zhong X. Targeted therapy in breast cancer: what's new? Swiss Med Wkly 2011;141:w13231.
51. Baselga J, Swain S. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer. 2010;10:489-91.
52. Amler L, Birkner M, Lin C, Moecks J, Strauss A. Predicting response to a HER inhibitor. US 7981418 B2, 2011.
53. Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011; 306: 171-9.
54. Lewis PG, Li G, Dugger D, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-90.
55. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab- DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28: 2698-704.
56. Burris HA, Rugo HS, Vukelja SJ, et al. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After Prior HER2-Directed Therapy. J Clin Oncol 2011; 29: 398-405.
57. Rabindran S, Discafani C, Rosfjord E, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004; 64: 3958-65.
58. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2- positive breast cancer. J Clin Oncol 2010; 28:1301-7.
59. Araújo A, Barata F, Barroso S, et al. Cost of cancer care in Portugal. Acta Med Port 2009; 22: 525-36.